PCNA: A silent housekeeper or a potential therapeutic target?

Trends in Pharmacological Sciences

Volumn 35, Issue 4, 2014, Pages 178-186

  Wang, Shao Chun ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; DISEASE ASSOCIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PEPTIDES; PROLIFERATING CELL NUCLEAR ANTIGEN; SIGNAL TRANSDUCTION;

EID: 84898773108     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.02.004     Document Type: Review

References (126)

1. M.B. Mathews et al. Identity of the proliferating cell nuclear antigen and cyclin Nature 309 1984 374 376
2. R. Bravo, and J.E. Celis A search for differential polypeptide synthesis throughout the cell cycle of HeLa cells J. Cell Biol. 84 1980 795 802
3. R. Bravo et al. Identification of a nuclear and of a cytoplasmic polypeptide whose relative proportions are sensitive to changes in the rate of cell proliferation Exp. Cell Res. 136 1981 311 319
4. T.S. Krishna et al. Crystallization of proliferating cell nuclear antigen (PCNA) from Saccharomyces cerevisiae J. Mol. Biol. 241 1994 265 268
5. P. Schurtenberger et al. The solution structure of functionally active human proliferating cell nuclear antigen determined by small-angle neutron scattering J. Mol. Biol. 275 1998 123 132
6. S.N. Naryzhny, and H. Lee Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer FEBS Lett. 584 2010 4292 4298
7. G. Maga, and U. Hubscher Proliferating cell nuclear antigen (PCNA): a dancer with many partners J. Cell Sci. 116 2003 3051 3060
8. G.L. Moldovan et al. PCNA, the maestro of the replication fork Cell 129 2007 665 679
9. H.D. Ulrich, and T. Takahashi Readers of PCNA modifications Chromosoma 122 2013 259 274
10. E. Warbrick The puzzle of PCNA's many partners Bioessays 22 2000 997 1006
11. T. Paunesku et al. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome Int. J. Radiat. Biol. 77 2001 1007 1021
12. Z. Kelman PCNA: structure, functions and interactions Oncogene 14 1997 629 640
13. K. Komatsu et al. PCNA interacts with hHus1/hRad9 in response to DNA damage and replication inhibition Oncogene 19 2000 5291 5297
14. I. Stoimenov, and T. Helleday PCNA on the crossroad of cancer Biochem. Soc. Trans. 37 2009 605 613
15. N. Mailand et al. Regulation of PCNA-protein interactions for genome stability Nat. Rev. Mol. Cell Biol. 14 2013 269 282
16. V. Witko-Sarsat et al. Proliferating cell nuclear antigen acts as a cytoplasmic platform controlling human neutrophil survival J. Exp. Med. 207 2010 2631 2645
17. B. Rosental et al. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44 J. Immunol. 187 2011 5693 5702
18. Y-H. Lo et al. Phosphorylation at tyrosine 114 of proliferating cell nuclear antigen (PCNA) is required for adipogenesis in response to high fat diet Biochem. Biophys. Res. Commun. 430 2013 43 48
19. J.S. Lee et al. Correlation between angiogenesis, apoptosis and cell proliferation in invasive ductal carcinoma of the breast and their relation to tumor behavior Anal. Quant. Cytol. Histol. 23 2001 161 168
20. I.R.K. Bukholm et al. Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas J. Clin. Pathol. 56 2003 368 373
21. F. Grossi et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers Eur. J. Cancer 39 2003 1242 1250
22. R. Heimann et al. Breast cancer metastatic phenotype as predicted by histologic tumor markers Cancer J. Sci. Am. 3 1997 224 229
23. L-F. Wang et al. Correlation between proliferating cell nuclear antigen and p53 protein expression and 5-year survival rate in nasopharyngeal carcinoma Am. J. Otolaryngol. 27 2006 101 105
24. M. Ebina et al. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer Cancer Res. 54 1994 2496 2503
25. L. Temmim et al. Evaluation of prognostic factors in male breast cancer Breast 10 2001 166 175
26. T. Haerslev et al. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas Breast Cancer Res. Treat. 37 1996 101 113
27. K.E. Tachibana et al. Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology J. Pathol. 205 2005 123 129
28. T. Visakorpi Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma J. Pathol. 168 1992 7 13
29. R. Kordek et al. Comparative evaluation of p53-protein expression and the PCNA and Ki-67 proliferating cell indices in human astrocytomas Pathol. Res. Pract. 192 1996 205 209
30. V. Padmanabhan et al. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer J. Clin. Pathol. 57 2004 1057 1062
31. T.M. Williams et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in TRAMP mice J. Biol. Chem. 280 2005 25134 25145
32. D. Dworakowska et al. Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer Lung Cancer 35 2002 35 41
33. R. Bravo, and H. Macdonald-Bravo Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites J. Cell Biol. 105 1987 1549 1554
34. F. Riva et al. Distinct pools of proliferating cell nuclear antigen associated to DNA replication sites interact with the p125 subunit of DNA polymerase delta or DNA ligase I Exp. Cell Res. 293 2004 357 367
35. S-C. Wang et al. Tyrosine phosphorylation controls PCNA function through protein stability Nat. Cell Biol. 8 2006 1359 1368
36. C. Hoege et al. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO Nature 419 2002 135 141
37. S.N. Naryzhny, and H. Lee The post-translational modifications of proliferating cell nuclear antigen: acetylation, not phosphorylation, plays an important role in the regulation of its function J. Biol. Chem. 279 2004 20194 20199
38. C. Choudhary et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 325 2009 834 840
39. E. Prosperi et al. Proliferating cell nuclear antigen complex formation induced by ultraviolet irradiation in human quiescent fibroblasts as detected by immunostaining and flow cytometry Exp. Cell Res. 205 1993 320 325
40. Y.W. Lam et al. Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells PLoS ONE 5 2010 e9075
41. M.T. Forrester et al. Proteomic analysis of S-nitrosylation and denitrosylation by resin-assisted capture Nat. Biotechnol. 27 2009 557 559
42. S. Bergink, and S. Jentsch Principles of ubiquitin and SUMO modifications in DNA repair Nature 458 2009 461 467
43. H.D. Ulrich Regulating post-translational modifications of the eukaryotic replication clamp PCNA DNA Repair 8 2009 461 469
44. H.D. Ulrich, and H. Walden Ubiquitin signalling in DNA replication and repair Nat. Rev. Mol. Cell Biol. 11 2010 479 489
45. R. Bravo, and J.E. Celis Changes in the nuclear distribution of cyclin (PCNA) during S-phase are not triggered by post-translational modifications that are expected to moderately affect its charge FEBS Lett. 182 1985 435 440
46. E. Prosperi et al. Proliferating cell nuclear antigen bound to DNA synthesis sites: phosphorylation and association with cyclin D1 and cyclin A Exp. Cell Res. 215 1994 257 262
47. A. Venturi et al. Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation Lab. Invest. 88 2008 995 1007
48. C. Miura et al. PCNA protein expression during spermatogenesis of the Japanese eel (Anguilla japonica) Zool. Sci. 19 2002 87 91
49. Y.N. Wang et al. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins Oncogene 29 2010 3997 4006
50. S-C. Wang, and M-C. Hung Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors Clin. Cancer Res. 15 2009 6484 6489
51. H.W. Lo, and M.C. Hung Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival Br. J. Cancer 94 2006 184 188
52. H. Zhao et al. The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer Oncogene 2013 10.1038/onc.2013.84
53. H. Zhao et al. Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer PLoS ONE 7 2012 e29416
54. J.V. Olsen et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks Cell 127 2006 635 648
55. T. Jenuwein, and C.D. Allis Translating the histone code Science 293 2001 1074 1080
56. J. Chen et al. A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo Nucleic Acids Res. 24 1996 1727 1733
57. F. Goubin, and B. Ducommun Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor Oncogene 10 1995 2281 2287
58. Y. Luo et al. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1 Nature 375 1995 159 161
59. E. Warbrick et al. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen Curr. Biol. 5 1995 275 282
60. Z.O. Jonsson et al. Regulation of DNA replication and repair proteins through interaction with the front side of proliferating cell nuclear antigen EMBO J. 17 1998 2412 2425
61. E. Warbrick PCNA binding through a conserved motif Bioessays 20 1998 195 199
62. J.B. Bruning, and Y. Shamoo Structural and thermodynamic analysis of human PCNA with peptides derived from DNA polymerase-delta p66 subunit and flap endonuclease-1 Structure 12 2004 2209 2219
63. J.M. Gulbis et al. Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA Cell 87 1996 297 306
64. A. De Biasio, and F.J. Blanco Proliferating cell nuclear antigen structure and interactions: too many partners for one dancer? Adv. Protein Chem. Struct. Biol. 91 2013 1 36
65. Z.Q. Pan et al. Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21 J. Biol. Chem. 270 1995 22008 22016
66. G. Kontopidis et al. Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design Proc. Natl. Acad. Sci. U.S.A. 102 2005 1871 1876
67. E. Warbrick A functional analysis of PCNA-binding peptides derived from protein sequence, interaction screening and rational design Oncogene 25 2006 2850 2859
68. D.I. Zheleva et al. A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics Biochemistry 39 2000 7388 7397
69. E. Warbrick et al. PCNA binding proteins in Drosophila melanogaster: the analysis of a conserved PCNA binding domain Nucleic Acids Res. 26 1998 3925 3932
70. K.M. Gilljam et al. Identification of a novel, widespread, and functionally important PCNA-binding motif J. Cell Biol. 186 2009 645 654
71. R. Muller et al. Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells PLoS ONE 8 2013 e70430
72. A. Bacquin et al. The helicase FBH1 is tightly regulated by PCNA via CRL4(Cdt2)-mediated proteolysis in human cells Nucleic Acids Res. 41 2013 6501 6513
73. A. Ciccia et al. Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress Mol. Cell 47 2012 396 409
74. H. Zhao et al. Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth Mol. Cancer Ther. 10 2011 29 36
75. S.K. Pal et al. Triple negative breast cancer: unmet medical needs Breast Cancer Res. Treat. 125 2011 627 636
76. Y.L. Yu et al. Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides PLoS ONE 8 2013 e61362
77. M. Chorev The partial retro-inverso modification: a road traveled together Biopolymers 80 2005 67 84
78. C. Punchihewa et al. Identification of small molecule proliferating cell nuclear antigen (PCNA) Inhibitor that disrupts interactions with PI-box proteins and inhibits DNA replication J. Biol. Chem. 287 2012 14289 14300
79. M. Actis et al. Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis Bioorg. Med. Chem. 21 2013 1972 1977
80. Z. Tan et al. Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth Mol. Pharmacol. 81 2012 811 819
81. Y.H. Lo et al. Epidermal growth factor receptor protects proliferating cell nuclear antigen from cullin 4A protein-mediated proteolysis J. Biol. Chem. 287 2012 27148 27157
82. N.M. Benight, and S.E. Waltz Ron receptor tyrosine kinase signaling as a therapeutic target Expert Opin. Ther. Targets 16 2012 921 931
83. P.K. Wagh et al. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis Adv. Cancer Res. 100 2008 1 33
84. A. Iwama et al. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family EMBO J. 15 1996 5866 5875
85. A. Follenzi et al. Cross-talk between the proto-oncogenes Met and Ron Oncogene 19 2000 3041 3049
86. P.K. Wagh et al. β-Catenin is required for Ron receptor-induced mammary tumorigenesis Oncogene 30 2011 3694 3704
87. P.K. Wagh et al. Conditional deletion of beta-catenin in mammary epithelial cells of Ron receptor, Mst1r, overexpressing mice alters mammary tumorigenesis Endocrinology 153 2012 2735 2746
88. O. Hantschel, and G. Superti-Furga Regulation of the c-ABL and BCR-ABL tyrosine kinases Nat. Rev. Mol. Cell Biol. 5 2004 33 44
89. S.S. Ganguly et al. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression Oncogene 31 2012 1804 1816
90. J. Lin, and R. Arlinghaus Activated c-Abl tyrosine kinase in malignant solid tumors Oncogene 27 2008 4385 4391
91. J. Lin et al. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1 Oncogene 26 2007 6989 6996
92. D. Srinivasan, and R. Plattner Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells Cancer Res. 66 2006 5648 5655
93. D. Srinivasan et al. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival Oncogene 27 2008 1095 1105
94. A. Sirvent et al. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells Oncogene 26 2007 7313 7323
95. H. Zhao et al. Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer Neoplasia 12 2010 214 223
96. S. Bhattacharyya et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylate Oncogene 28 2009 1285 1297
97. C.F. Singer et al. Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors Endocr. Relat. Cancer 11 2004 861 869
98. X. He et al. c-Abl regulates estrogen receptor α transcription activity through its stabilization by phosphorylation Oncogene 29 2010 2238 2251
99. A.S. Oh et al. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells Mol. Cell. Biol. 28 2008 6580 6593
100. H. Zhao et al. Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-oncogene in breast cancer Mol. Carcinog. 50 2011 383 389
101. R.B. Jones et al. A quantitative protein interaction network for the ErbB receptors using protein microarrays Nature 439 2006 168 174
102. R. Plattner et al. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF Genes Dev. 13 1999 2400 2411
103. Y.H. Lo et al. Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016) Anticancer Res. 31 2011 789 795
104. P.E. Bechtel et al. A unique form of proliferating cell nuclear antigen is present in malignant breast cells Cancer Res. 58 1998 3264 3269
105. L.H. Malkas et al. A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker Proc. Natl. Acad. Sci. U.S.A. 103 2006 19472 19477
106. Z.T. Hammoud et al. A novel biomarker for the detection of esophageal adenocarcinoma J. Thorac. Cardiovasc. Surg. 133 2007 82 87
107. X. Wang et al. Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer Prostate 71 2011 748 754
108. D.J. Hoelz et al. The discovery of labile methyl esters on proliferating cell nuclear antigen by MS/MS Proteomics 6 2006 4808 4816
109. A.L. Groehler, and D.A. Lannigan A chromatin-bound kinase, ERK8, protects genomic integrity by inhibiting HDM2-mediated degradation of the DNA clamp PCNA J. Cell Biol. 190 2010 575 586
110. J. Mendelsohn, and J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J. Clin. Oncol. 21 2003 2787 2799
111. S. Modi et al. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer Clin. Breast Cancer 7 2006 270 277
112. R.S. Finn et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer J. Clin. Oncol. 27 2009 3908 3915
113. C.G. Havens et al. Direct role for proliferating cell nuclear antigen (PCNA) in substrate recognition by the E3 ubiquitin ligase CRL4-Cdt2 J. Biol. Chem. 287 2012 11410 11421
114. C.G. Havens, and J.C. Walter Mechanism of CRL4(Cdt2), a PCNA-dependent E3 ubiquitin ligase Genes Dev. 25 2011 1568 1582
115. D. Banks et al. L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes Cell Cycle 5 2006 1719 1729
116. H. Wang et al. Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage Mol. Cell 22 2006 383 394
117. S. Jia et al. Ubiquitin ligase component Cul4 associates with Clr4 histone methyltransferase to assemble heterochromatin Nat. Cell Biol. 7 2005 1007 1013
118. L.A. Higa et al. CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation Nat. Cell Biol. 8 2006 1277 1283
119. J. Hannah, and P. Zhou Regulation of DNA damage response pathways by the cullin-RING ubiquitin ligases DNA Repair (Amst.) 8 2009 536 543
120. J. Guerrero-Santoro et al. The cullin 4B-based UV-damaged DNA-binding protein ligase binds to UV-damaged chromatin and ubiquitinates histone H2A Cancer Res. 68 2008 5014 5022
121. M.G. Kapetanaki et al. The DDB1-CUL4ADDB2 ubiquitin ligase is deficient in xeroderma pigmentosum group E and targets histone H2A at UV-damaged DNA sites Proc. Natl. Acad. Sci. U.S.A. 103 2006 2588 2593
122. Q. Dai, and H. Wang Cullin 4 makes its mark on chromatin Cell Div. 1 2006 14
123. J.P. Quivy et al. A CAF-1 dependent pool of HP1 during heterochromatin duplication EMBO J. 23 2004 3516 3526
124. C. Maison, and G. Almouzni HP1 and the dynamics of heterochromatin maintenance Nat. Rev. Mol. Cell Biol. 5 2004 296 304
125. R.A. Poot et al. The Williams syndrome transcription factor interacts with PCNA to target chromatin remodelling by ISWI to replication foci Nat. Cell Biol. 6 2004 1236 1244
126. S. Roa et al. Ubiquitylated PCNA plays a role in somatic hypermutation and class-switch recombination and is required for meiotic progression Proc. Natl. Acad. Sci. U.S.A. 105 2008 16248 16253